Precision antimicrobial stewardship for Clostridioides difficile prevention (PASTCDI)

Information

  • Research Project
  • 10056575
  • ApplicationId
    10056575
  • Core Project Number
    R03HS027208
  • Full Project Number
    1R03HS027208-01A1
  • Serial Number
    027208
  • FOA Number
    PA-18-794
  • Sub Project Id
  • Project Start Date
    7/2/2020 - 4 years ago
  • Project End Date
    6/30/2022 - 2 years ago
  • Program Officer Name
    GRAY, DARRYL T
  • Budget Start Date
    7/2/2020 - 4 years ago
  • Budget End Date
    6/30/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    7/2/2020 - 4 years ago
Organizations

Precision antimicrobial stewardship for Clostridioides difficile prevention (PASTCDI)

Project Summary Clostridioides difficile infection (CDI) is an important healthcare-associated infection and a significant driver of poor patient outcomes and preventable cost. An existing bundle of antimicrobial stewardship (AMS) methods of CDI prevention are limited by difficulties identifying high-risk patients most likely to benefit from interventions. Recently we have developed a machine learning classification tool capable of accurately identify risk of developing CDI in hospitalized patients. Here we propose adding and rigorously testing this highly innovative precision medicine approach to CDI prevention within a robust, real-world AMS infrastructure Objective: To decrease CDI incidence by implementing an electronic health record-integrated CDI-risk classification tool within a framework of precision-medicine AMS. Specific Aim: Measure the effect of implementing a real-time CDI-risk classification tool to guide AMS efforts for CDI prevention among high-risk patients. The primary outcome will be hospital-associated CDI incidence. We will measure outcomes in patients identified as high-risk by the risk classification tool, comparing a 24- month pre-implementation period with a 12-month post-implementation period using interrupted time series (ITS) segmented regression. Secondary outcomes will include antimicrobial utilization rates, CDI test ordering, hospital length of stay, total cost, tool use, and AMS satisfaction Hypothesis: We hypothesize that tool implementation will result in a 35% relative reduction in CDI incidence, which aligns well with the lower end of estimates of bundle effect in prior studies. Significance: While evidence supports the efficacy of AMS interventions for CDI-prevention in general, our proposal is the first to our knowledge to employ a precision-medicine approach to CDI prevention. This high- impact, precision medicine proposal, based on extensive, sound preliminary data has a high probability of success.

IC Name
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY
  • Activity
    R03
  • Administering IC
    HS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    37428
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    226
  • Ed Inst. Type
  • Funding ICs
    AHRQ:37428\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HSQR
  • Study Section Name
    Healthcare Patient Safety and Quality Improvement Research
  • Organization Name
    IHC HEALTH SERVICES, INC.
  • Organization Department
  • Organization DUNS
    072955503
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    841111633
  • Organization District
    UNITED STATES